Pelago Launches Sona, a Voice-First AI for Mental Health
Pelago (pelagohealth.com), the YC-backed virtual clinic known for its outcomes-based substance use treatment, is expanding into mental health with Sona, a voice-first AI tool designed to fill the gap between everyday emotional struggles and clinical therapy sessions.
The product, announced today by CEO Yusuf Sherwani, is Pelago's first foray beyond substance use. The company argues that the mental health care system has a fundamental allocation problem: too many people are routed into traditional therapy regardless of what they actually need, driving up costs without improving outcomes. Sherwani pointed to SAMHSA data indicating that nearly half of adults receiving mental health treatment don't meet criteria for a diagnosable condition in a given year.
Pelago, formerly Quit Genius, is a virtual clinic for substance use management that was founded in 2017 by Maroof Ahmed, Yusuf Sherwani, and Sarim Siddiqui, who all met at medical school. The company operates a 100% fees-at-risk model, tying revenue directly to clinical outcomes, a pricing structure it's now extending to Sona.
In 2024, Pelago raised a $58 million Series C led by Atomico. Earlier rounds were led by Kinnevik AB (Series B) and Octopus Ventures (Series A), with seed backing from Y Combinator, Pioneer Fund, and angels like Instacart co-founder Max Mullen.
Sona is voice-first by design. According to Pelago's Chief Scientific Officer Suzette Glasner, that's because people tend to be more honest when speaking than when typing. The system listens for clinical signals in tone, pacing, and emotional register during conversations. Behind each interaction, Pelago's clinical team reviews performance, refines protocols, and retains authority over clinical decisions. Sona doesn't diagnose or prescribe; when a conversation warrants human judgment, it routes the member to a clinician.
"Sona takes on what doesn't need a clinician, so clinical capacity reaches the people who do, without inflating healthcare costs."
Safety is central to how Pelago is positioning the product. The company evaluated Sona against two open benchmarks for mental health AI: VERA-MH and MindEval. Sona scored a perfect 100 on VERA-MH's risk detection sub-score and scored highest of any tested system on all five clinical dimensions of MindEval, according to Pelago's blog post detailing the methodology.
Pelago also published early pilot data showing that among members with baseline depression or anxiety, 71% reduced at least one GAD/PHQ severity tier within four weeks, with an average symptom score reduction of 53%. On the CDC's Healthy Days measure, members gained an average of 2.5 healthy days per person per month. The company says it has submitted a study on Sona's suicidality detection and escalation protocol for peer review, which it describes as the first published account of keeping humans in the loop for suicidality screening in a generative AI mental health tool.
Sona is already being piloted through employers. Sona by Pelago is available at no cost to eligible employees and their dependents, as part of a pilot program running through May 2027. Marina Pearson, VP of Global Benefits and Talent Well-Being at Lumen, said the company had already built trust with Pelago through substance use treatment and that employees have responded positively to Sona's referral capabilities and outcomes-based pricing.
For Pelago, the thesis is straightforward: the same approach that brought substance use treatment costs down from roughly $30,000 to under $3,000 per person can be applied to mental health. Whether employers will embrace an AI-first layer in behavioral health at scale is the question the pilot is designed to answer.